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Abstract Vascular endothelial growth factor pathway inhibitors (VEGFi), used as anti-angiogenic drugs to treat cancer are as-
sociated with cardiovascular toxicities through unknown molecular mechanisms. Endothelial cell-derived micropar-
ticles (ECMPs) are biomarkers of endothelial injury and are also functionally active since they influence downstream
target cell signalling and function. We questioned whether microparticle (MP) status is altered in cancer patients
treated with VEGFi and whether they influence endothelial cell function associated with vascular dysfunction.
Plasma MPs were isolated from cancer patients before and after treatment with VEGFi (pazopanib, sunitinib, or sor-
afenib). Human aortic endothelial cells (HAECs) were stimulated with isolated MPs (106 MPs/mL). Microparticle
characterization was assessed by flow cytometry. Patients treated with VEGFi had significantly increased levels of
plasma ECMP. Endothelial cells exposed to post-VEGFi treatment ECMPs induced an increase in pre-pro-ET-1
mRNA expression, corroborating the increase in endothelin-1 (ET-1) production in HAEC stimulated with vatalanib
(VEGFi). Post-VEGFi treatment MPs increased generation of reactive oxygen species in HAEC, effects attenuated
by ETA (BQ123) and ETB (BQ788) receptor blockers. VEGFi post-treatment MPs also increased phosphorylation
of the inhibitory site of endothelial nitric oxide synthase (eNOS), decreased nitric oxide (NO), and increased
ONOO- levels in HAEC, responses inhibited by ETB receptor blockade. Additionally, gene expression of proinflam-
matory mediators was increased in HAEC exposed to post-treatment MPs, effects inhibited by BQ123 and BQ788.
Our findings define novel molecular mechanism involving interplay between microparticles, the ET-1 system and
endothelial cell pro-inflammatory and redox signalling, which may be important in cardiovascular toxicity and hyper-
tension associated with VEGFi anti-cancer treatment. New and noteworthy: our novel data identify MPs as bio-
markers of VEGFi-induced endothelial injury and important mediators of ET-1-sensitive redox-regulated pro-
inflammatory signalling in effector endothelial cells, processes that may contribute to cardiovascular toxicity in
VEGFi-treated cancer patients.
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This article is part of the Spotlight Issue on Cardio-oncology.
1. Introduction
Vascular endothelial growth factor (VEGF) is an important growth factor
produced by several cell types in the vascular and haematopoietic sys-
tems with crucial functions in vascular development and function. VEGF
is also produced under pathological conditions by cancer cells and
promotes formation of new blood vessels (angiogenesis), important in
tumourigenesis. VEGFA is the most biologically active isoform1 and
interacts with three tyrosine kinase receptors (VEGFR1-3). In endothe-
lial cells, VEGFA through VEGFR1/2 initiates signalling through tyrosine
kinases resulting in cell growth, migration, increased permeability and va-
sodilation, mediated via nitric oxide (NO), and prostacyclin.1–4 These
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are major processes involved in normal vasculogenesis and function,
however, in a cancer environment increased VEGF signalling promotes
uncontrolled angiogenesis, leading to tumour growth and metastasis.
VEGF inhibitors (VEGFi) are potent anti-angiogenic drugs that have
had major impact as anti-cancer drugs in the treatment of solid tumours.
They have prolonged survival in some cancer patients and are increas-
ingly being used, either as monotherapy or as part of combination regi-
mens, as first- and/or second-line treatment for several cancers,
including renal cell, colorectal, and hepatocellular cancer.5 However,
VEGFi anti-cancer therapy is associated with significant cardiovascular
toxicity with almost all patients developing hypertension.6–9 VEGF inhibi-
tion is also associated with thromboembolic disease, left ventricular sys-
tolic dysfunction, heart failure, and myocardial ischaemia. Common to
these cardiovascular pathologies is endothelial dysfunction and vascular
injury. Potential mechanisms implicated in VEGFi-induced hypertension
include increased endothelin-1 (ET-1) levels, renin–angiotensin system
activation, endothelial cell apoptosis, and microvascular rarefaction.6,8,9
Recently, we demonstrated in in vivo and in vitro studies that vatalanib, a
VEGFi, increased the generation of reactive oxygen species (ROS) in vas-
cular cells and decreased activation of endothelial nitric oxide synthase
(eNOS) and production of nitric oxide (NO) resulting in endothelial dys-
function and vascular hypercontractility in VEGFi-treated mice.10 Many
cellular processes underlie these vascular changes including production
of endothelial microparticles, which may have relevance in the context
of angiogenesis, because circulating microparticles are associated with
VEGF expression, microvascular density, and angiogenesis in oral
cancer.11
Cell-derived microparticles are small membranous structures (0.1–
1lm) shed by eukaryotic cells upon cell activation or stress.12,13 They
carry membrane markers and cytosolic molecules derived from parent
cells including microRNAs, DNA, RNA, phospholipids, and proteins and
are detected in the circulation in physiologic and pathologic conditions.
Microparticles reflect the parental cell profile and accordingly are consid-
ered as biomarkers of activation status of the parent cell from which
they derived. In cardiovascular diseases associated with vascular injury
(hypertension, atherosclerosis, and coronary artery disease) circulating
levels of endothelial cell-derived microparticles (ECMPs) are increased
and appear to reflect endothelial cell activation and vascular dysfunc-
tion.12,14,15 In addition to their biomarker role, microparticles are biovec-
tors that carry bioactive molecules, which have functional effects on
effector target cells. Recent studies reported that microparticles directly
affect endothelial function by increasing endothelial cell oxidative stress
and inflammation, reducing NO production, promoting endothelial cell
senescence, and stimulating platelet and monocyte endothelial adhe-
sion.16–19
Considering the multiple characteristics of microparticles they may be
considered as both prognostic biomarkers and pathogenic effectors in
pathological conditions. In the present study, we questioned whether mi-
croparticle status is altered in cancer patients treated with VEGFi and
whether microparticles from VEGFi-treated patients influence effector
endothelial cells.
2. Methods
All experimental studies using human plasma samples comply with the
Declaration of Helsinki and has full West of Scotland Research Ethics
Committee approval (REC 10/S0704/18). Informed consent was
obtained from all subjects.
2.1 Study population
The eligibility criteria for this study included: no prior tyrosine kinase in-
hibitor (TKI) treatment; no diagnosis of malignant disease; patients at-
tending the Beatson West of Scotland Cancer Centre for treatment;
over 18 years of age; no medical or psychiatric illness that would contra-
indicate blood donation. All patients gave signed informed consent prior
to sample collection and study protocol aligned with the principles set
out in the Declaration of Helsinki. The median age of patients was
64 years (39–86 years).
Forty-two patients were initially recruited into the study, however,
due to various factors (failure to collect post-treatment samples, inade-
quate blood collection, patient died), samples from only 39 patients
were fully studied where we were able to isolate microparticles before
and after VEGFi treatment.
2.2 Blood samples
Blood samples were collected in heparinized tubes from cancer patients
pre-treatment and post-treatment with VEGFi (pazopanib, sunitinib, or
sorafenib) in heparinized tubes. Blood was centrifuged for 10min at
2000 rpm at room temperature to obtain platelet-poor plasma superna-
tant. Plasma was collected and centrifuged for 20min at 1500 g to obtain
platelet-free plasma (PFP) supernatant. PFP was aliquoted and stored at
-80C. Clinical information is detailed in Supplementary material online,
Table S1.
All studies comparing effects of pre-treatment and post-treatment
microparticles (MPs) were always performed using the same set of
patients since the main aim of this study was to compare the effects of
isolated MPs before and after VEGFi-treatment.
2.3 Characterization of circulating
microparticles
For microparticles studies, technical triplicates were performed for all
samples. The PFP was thawed and 50mL of PFP was incubated on ice in
the dark for 30min with 5mL of anti-CD42b-FITC (final dilution 1:600)
(clone HIP1, BD-Pharmingen) and 6mL of anti-CD31-APC/Cy7 (final di-
lution 1:600) (clone WM59, Biolegend). Antibodies were carefully ti-
trated in order to identify the best working concentration. Subsequently,
2.5mL of Annexin-V-alexa 647 (Biolegend); 3mL of 0.5mol/L CaCl2, and
233.5mL of NaCl 0.9% were added to make a final reaction volume of
300mL. The specificity of antibodies was also checked using appropriate
isotype controls—FITC Mouse IgG1 (clone MOPC-21, BD-
Pharmingen), APC/Cy7 Mouse IgG1 (clone WM59, Biolegend). Every
sample was processed separately by flow cytometry. We did not pool
any samples. Microparticles were defined as particles identified between
0.1mm and 1mm in diameter as assessed by flow cytometry (FACS
Canto II—BD Biosciences). Microparticle events were measured by
FACS at constant medium flow for 4min. Events were gated according
to size (0.1–1mm) at forward scatter and side scatter, both in log scale,
using 1mm size beads as a reference (#F13839; Molecular Probes, Life
Technologies). Microparticles were characterized based on membrane
marker expression: total microparticles were Annexin Vþ (MPs), plate-
let microparticles (PMP) were Annexin Vþ CD31þ CD42bþ, and
ECMPs were Annexin Vþ CD31þ CD42b-. We also probed PMP and
ECMP for VEGFR2 expression (PE mouse anti-human CD309, Clone
89106, BD-Pharmingen) (Figure 1). Experiments were also performed us-
ing the isotype control PE Mouse IgG1 (clone MOPC-21, BD-
Pharmingen). MPs concentration was calculated using counting beads as
a known standard with 1mL of PFP used for normalization. FACS data
Microparticles, VEGF inhibitors, and endothelial cells 979
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were analysed using Flow JoTM software (v10.0.7, Tree Star, Inc., OR,
USA). The absolute numbers of microparticles, ECMPs and PMPs were
calculated using the following formula: MP/mL = A  (B/C)  20, where
A = total number of MP events observed in the constant flow of 4min;
B = total number of counting beads added in the FACS tube before
acquisition; C = total number of beads counted in the constant flow
of 4min; and 20 is the correction factor for 1mL of plasma. These proto-
cols were based on previous studies.16,20–22 Statistical analysis was per-
formed on the mean value derived from the technical triplicates.
2.4 Isolation of microparticles
Plasma samples (1mL) were placed in ultracentrifugation tubes and 2mL
of sterile/filtered PBS was added. Samples were centrifuged for 60min at
20 000 g at 4C (OptimaTM TL Ultracentrifuge Beckman Coulter). The
microparticle pellet was resuspended in lysis buffer (100mL) for immu-
noblotting assays or in filtered and sterile PBS for cell stimulation
(200mL). MPs size was verified using the Nanosight technology
(NanosightVR LM14) in plasma samples diluted 1:1000 in sterile phospha-
tase buffer saline (PBS). Data were acquired using the Nanosight NTA
3.2 software.
2.5 Cell culture
For cell-based studies to assess effects of patients microparticles on en-
dothelial cell signalling and function we used human aortic endothelial
cell (HAEC) (ATCCVR , Middlesex, UK; PCS-100-011). HAEC were cul-
tured in Endothelial Cell Growth Medium (PromocellVR ) supplemented
with Penicillin/Streptomycin (50mg/mL) and Endothelial Cell Growth
Medium Supplement (10mL; PromocellVR ). For functional studies, conflu-
ent cells were made quiescent for 2 h in low-serum medium containing
0.5% foetal bovine serum (FBS) and stimulated with total microparticles
(106 MPs/mL) isolated from patients pre-VEGFi and post-VEGFi.
Quiescent cells were used because this provides a system where molec-
ular events can be studied in controlled conditions, where cells are not
actively dividing. In addition, serum-free conditions avoid the potential
for cell activation because serum contains growth factors and other pro-
teins that trigger signalling and cell growth. This is especially relevant in
our study, where we are interfering with growth factor (VEGF) signalling
through VEGFi.
All studies comparing effects of pre-treatment and post-treatment
MPs were performed using the same set of patients. In some experi-
ments, cells were pre-treated with BQ123 (ETA receptor antagonist;
1mmol/L) or BQ788 (ETB receptor antagonist; 1mmol/L).
2.6 Experimental protocols
2.6.1 Nitric oxide production
Production of NO was determined using the NO fluorescent probe
diacetate 4-amino-5-methylamino-20,70-difluorofluorescein diacetate
(DAF-FM; Life Technologies, Molecular Probes, Paisley, UK). HAEC
were load with DAF-FM diacetate (final concentration 5mmol/L, 30min)
in serum free media, kept in the dark, and maintained at 37C, as we pre-
viously described.23 In brief, cells were washed to remove exceeding
probe. Medium was replaced and incubated for an additional 10min to
allow complete de-esterification of the intracellular diacetates. Cells
were stimulated with total microparticles (106 MPs/mL; 15min) isolated
from patients post-treatment with VEGFi in the absence or presence of
BQ788 (ETB antagonist, 1mmol/L, 30min preincubation). Cells were
washed with phosphate-buffered saline (PBS) and harvested with mild
trypsinization at 0.025%. Trypsin was inactivated with soybean trypsin in-
hibitor (0.025%) in PBS (1:1). After washing, the pellet was transferred to
a black 96 well microplate (BD Falcon, Loughborough, UK). The DAF-
FM fluorescence was assessed with a spectrofluorometer at excitation/
emission wavelengths of 495/515 nm. Fluorescence intensity was nor-
malized to the protein concentration and expressed as fluorescence
emission/mg of protein.
2.6.2 Lucigenin-enhanced chemiluminescence
Lucigenin-enhanced chemiluminescence assay was used to determine
NADPH oxidase activity in HAEC as we previously described.24 Cells
were stimulated with total microparticles (106 MPs/mL) isolated from
patients pre-VEGFi and post-VEGFi treatment for different time periods.
In some experiments, 30min prior to stimulation with MPs, cells were
pre-incubated with BQ123 and BQ788. In brief, stimulated cells were
washed with ice-cold PBS and harvested in lysis buffer (20mmol/L of
KH2PO4, 1mmol/L of EGTA, 1lg/mL of aprotinin, 1lg/mL of leupeptin,
1lg/mL of pepstatin, and 1mmol/L of PMSF). The sample of 50mL were
added to a suspension containing 175ll of assay buffer (50mmol/L of
KH2PO4, 1mmol/L of EGTA, and 150mmol/L of sucrose) and lucigenin
(5lmol/L). Luminescence was measured with a luminometer
(AutoLumat LB 953, Berthold) before and after stimulation with
NADPH (100mmol/L). A buffer blank was subtracted from each reading.
The results are expressed as a fold change in arbitrary units per milligram
of protein, as measured by the BCA assay.
2.6.3 Measurement of nitrotyrosine levels
Nitrotyrosine, a measure of peroxynitrite (ONOO-) formation, was
assessed in cells using an ELISA kit (#ab113848, Abcam, Cambridge,
UK), according to manufacturer’s instructions. The plate was read after
A B
C D
E
F
Figure 1 Representative flow cytometric multicolour gating strategy
used to analyse number of MPs. (A) Location of 1mm beads used to
gate MP events according to size. (B) Representative of MPs events
identified according to size (<1mm). (C) Annexin V positive events
(MPs). (D) PMPs (Annexin Vþ CD31þ CD42bþ) and ECMPs
(Annexin Vþ CD31þ CD42b-) populations were identified. (E, F)
VEGFR2-expressing PMPs (Annexin Vþ CD31þ CD42bþ CD309þ)
and ECMPs (Annexin Vþ CD31þ CD42b- CD309þ) were selected.
980 K.B. Neves et al.
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stop the reaction by adding stop solution at absorbance of 450 nm using
a microplate reader. Results were normalized to protein concentration.
2.6.4 Quantitative real-time PCR
mRNA expression for pre-pro-ET-1, tumour necrosis factor-a (TNF-a),
interleukin-6 (IL-6), monocytes chemoattractant protein-1 (MCP-1), in-
ducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and
vascular cell adhesion molecule-1 (VCAM-1) was measured by quantita-
tive real-time PCR (Applied Biosystems) in non-stimulated (NS) or total
microparticles-stimulated HAEC (8h). In brief, total RNA was extracted
from cells using QIAzol (Qiagen, Manchester, UK), treated with RNase-
free DNAse I, and 2lg of RNA was reverse transcribed in a reaction
containing 100lg/mL oligo-dT, 10mmol/L of 20-deoxynucleoside 50-tri-
phosphate, 5 First-Strand buffer, and 2lL of 200-U reverse transcrip-
tase. For real-time PCR amplification, 3lL of each reverse transcription
product were diluted in a reaction buffer containing 5lL of SYBR Green
PCR master mix and 300nmol/L of primers in a final volume of 10lL
per sample. The reaction conditions consisted of two steps at 50C for
2min and 95C for 2min, followed by 40 cycles of three steps, 15-s de-
naturation at 95C, 60-s annealing at 60C, and 15 s at 72C. The relative
mRNA expression (target gene/Gapdh housekeeping gene) was calcu-
lated by the 2-DDCt method.25 Primers used are detailed in
Supplementary material online, Table S2.
2.6.5 Immunoblotting
Immunoblotting was used to assess ET-1 expression in isolated micro-
particles (1:1000, Santa Cruz #sc-517436, Middlesex, UK) and phos-
phorylation of eNOS (1:1000, Cell Signaling #9574, Hitchin, UK) in
HAEC exposed to isolated MPs. In brief, cells were homogenized in lysis
buffer [(in mmol/L) sodium pyrophosphate 50, NaF 50, NaCl 5, EDTA 5,
EGTA 5, HEPES 10, Na3VO4 2, PMSF 50, Triton 100 0.5%, and leupep-
tin/aprotinin/pepstatin 1mg/mL] and sonicated for 5 s. Proteins (30mg)
were separated by electrophoresis on 12% and 7.5% SDS polyacryl-
amide gel, according to the molecular weight of the protein target, and
transferred to a nitrocellulose membrane. Non-specific binding sites
were blocked with 3% non-fatty dried milk in Tris-buffered saline solu-
tion with Tween (TBS-T) for 1 h at room temperature. Membranes
were probed with anti-phosphorylated (Thr495) eNOS overnight at 4C.
Membranes were then washed in TBS-T and incubated with secondary
fluorescence-coupled antibodies (LI-COR Biosciences, Cambridge, UK)
in 1% BSA for 1 h. Membranes were scanned by an infrared laser scanner
(Odyssey Clx, LI-COR Biosciences) and image analysis was performed
using Image StudioTM Software. Protein expression levels were normal-
ized to loading controls and expressed as absolute values or percentage
(%) of the control. The signal from the bands of interest was plotted us-
ing GraphPad PrismVR software.
2.7 Effects of VEGFi on endothelial
cell-derived ET-1 production
ET-1 levels were measured in media from HAEC exposed to vatalanib
(100 nmol/L; 8 h) by colorimetric (532–535 nm) assay according to the
manufacturer’s instructions (R&D Systems #QET00B, Abingdon, UK).
2.8 Statistical analysis
Statistical analysis was performed using GraphPad Prism 3.0 (GraphPad
Software Inc., San Diego, CA, USA). Data are presented as means ± stan-
dard error of the mean (SEM). Groups were compared using Student’s t-
test when differences between two groups were analysed. One-way
analysis of variance (ANOVA) and the Tukey’s post-test were used to
evaluate the statistical significance of the differences between three or
more groups. Results of statistical tests with P<0.05 were considered
significant.
3. Results
3.1 VEGF inhibition increases ECMP
release
The strategy to define microparticles is shown in Figure 1. We show a
representative from our PFP samples to exemplify our gating strategy to
analyse our data. In Figure 2, we show a representative from a single do-
nor for the pre-treatment and post-treatment bars. Each sample had a
different flow cytometry run; no pooled samples were used for the flow
cytometry experiments in this study.
Microparticle membranes possess phosphatidylserine that specifically
binds to Annexin V. Total microparticles were gated first by size
(<1mm) using size reference beads and thereafter gated for Annexin V
positive events (Annexin Vþ).
Of the 42 patients originally recruited into the study, only 39 were
fully studied with samples obtained pre-treatment and post-treatment.
In Figure 2, we provide results for all initially recruited 42 patients from
the pre-treatment group, however, studies with post-treatment data re-
flect 39 patients.
A similar number of Annexin Vþ microparticles was found in plasma
from cancer patients before and after treatment with VEGFi indicating
that the total number of circulating microparticles was unchanged by
VEGFi treatment (Figures 1B, C and 2A). However, there were differen-
ces in the sub-sets of microparticles following treatment. As shown in
Figures 1D and 2B, the number of ECMPs as determined by
CD31þCD41- labelling was increased following treatment, whereas the
number of PMPs, determined as CD31þCD42þ labelling
(Supplementary material online, Figure S1) was unchanged.We also eval-
uated expression of VEGFR2 in ECMPs and PMPs. VEGFi treatment did
not influence expression of VEGFR2 in ECMP or PMP (Supplementary
material online, Figure S1A and C). Phosphatidylserine expression in
Annexin Vþ MPs and the mean size of MPs was not different between
groups (Supplementary material online, Figure S2A and B). The number
of data points shown in Supplementary material online, Figure S1 is less
than that in other figures because not all samples were positive for
CD31, CD42b, or VEGFR2, which means that not all MPs isolated from
our patient’s blood samples expressed VEGFR2, or they may have been
derived from platelets or ECs.
3.2 Interplay between microparticles and
the ET-1 system
ET-1 is a potent vasoconstrictor and increased levels of ET-1 have been
observed in patients and experimental animal models treated with
VEGFi.26–29 In this context, ET-1 has been implicated in vascular dysfunc-
tion and hypertension in cancer patients treated with VEGFi. To explore
whether microparticles act as carriers for ET-1, we assessed ET-1 ex-
pression in circulating microparticles from cancer patients before and af-
ter VEGFi treatment. As shown in Figure 3A, ET-1 is present in
microparticles, but levels were unaffected by VEGFi. We next explored
the possibility that microparticles influence the ET-1 system in effector
endothelial cells. As shown in Figure 3B, HAEC stimulated with isolated
microparticles post-treatment increased pre-pro-ET-1 gene expression,
Microparticles, VEGF inhibitors, and endothelial cells 981
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a response which was not observed in non-stimulated cells or HAEC
stimulated with pre-VEGFi treatment microparticles (Figure 3B). To as-
sess direct effects of VEGFi on endothelial cells, we treated HAECs with
vatalanib. As shown in Figure 3C, vatalanib significantly increased produc-
tion of ET-1.
3.3 Microparticles from VEGFi-treated
cancer patients influence endothelial cell
production of ROS and NO through
ET-1-dependent processes
Human endothelial cells exposed to post-VEGFi treatment micropar-
ticles showed an increase in NADPH-dependent O2
- generation
(Figure 4A). These effects were inhibited by BQ123 and BQ788, antago-
nists of ETA and ETB receptors, respectively (Figure 4B). No ROS effects
were observed in HAEC stimulated with pre-VEGFi treatment
microparticles.
In HAECs stimulated with post-VEGFi treatment microparticles phos-
phorylation of the inhibitory motif (Thr495) of eNOS was increased
15min after stimulation (Figure 5A). This was associated with a reduction
in NO production in HAEC (Figure 5C). Pre-exposure of HAEC to
BQ788 (Figure 5B and C) inhibited microparticle-induced effects on
eNOS phosphorylation and NO production. In addition, post-VEGFi
treatment microparticles promoted an increase in ONOO- levels in
HAEC, which was reduced by the ETB receptor antagonist (Figure 5D).
3.4 Microparticles from VEGFi-treated
cancer patients modulate pro-inflammatory
signalling in endothelial cells
Human endothelial cells stimulated with microparticles obtained
from cancer patients post-VEGFi treatment induced a significant in-
crease in gene expression of pro-inflammatory markers including
TNF-a, IL-6, MCP-1, iNOS, COX-2, and VCAM-1 (Figures 6A–F).
These effects were reduced in HAEC pre-exposed to BQ123 and
BQ788 (Figure 6), indicating that the pro-inflammatory responses in-
duced by post-VEGFi treatment microparticles are mediated through
ET-1-dependent processes.
4. Discussion
Major findings from the present study demonstrate that, in cancer
patients treated with VEGFi, (i) circulating levels of endothelial micropar-
ticles, but not PMP, are increased, (ii) microparticles express VEGFR2
and carry ET-1, (iii) microparticles undergo a functional change to a pro-
inflammatory phenotype, and (iv) microparticles stimulate endothelial
cell signalling and ET-1 production through ET-1-dependent processes.
Our study suggests that in cancer patients, antiangiogenic drugs, such as
VEGFi, promote endothelial dysfunction, and formation of endothelial
microparticles, which are biologically functional units that induce endo-
thelial cell activation and inflammation. This feedforward system seems
to be mediated through increased production of endothelial-derived ET-
1. Our novel findings define a new mechanism involving interplay be-
tween microparticles, the ET-1 system and endothelial cell pro-
inflammatory and redox signalling, which may be important in cardiovas-
cular toxicity and hypertension associated with VEGFi anti-cancer
treatment.
Microparticles are increasingly being recognized as important bioac-
tive effectors in many pathologic processes, such as cardiovascular15 and
inflammatory30 diseases, preeclampsia,31 and cancer.32 Growing evi-
dence shows that ECMPs play a crucial role in cardiovascular diseases by
causing endothelial injury through processes involving oxidative stress
and impaired vasorelaxation.33,34 Here we found that, in cancer patients
treated with VEGFi, circulating levels of ECMPs were increased,
A B
C D
Figure 2 VEGFi increase ECMPs. (A) Representative of MPs events identified in plasma from patients pre-treatment and post-treatment with VEGFi.
(B) Representative of ECMPs events identified pre-treatment and post-treatment with VEGFi. (C, D) Scatter plot graphs representing the total number of
MPs and ECMPs, respectively identified in plasma pre-treatment and post-treatment with VEGFi (n=32–39). Results represent the mean ± SEM. Data
were analysed using t-test. *P<0.05 vs. pre-treatment.
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.suggesting that this may reflect underlying endothelial damage caused by
VEGFi treatment. This is supported by previous studies, which demon-
strated that anti-angiogenic VEGFi are associated with endothelial dys-
function and vascular injury.26,35–37We previously showed that vatalanib
(VEGFi) causes vascular dysfunction through redox-sensitive processes,
which is translated to endothelial dysfunction, vascular hypercontractil-
ity, and cardiovascular and renal oxidative stress.10 The fact that the total
number of microparticles as well as the PMP fraction were not altered
by VEGFi indicates that effects are cell-specific and that not all cell types
undergomicroparticle shedding in response to treatment.
Microparticles also act as transport vehicles for a wide range of pro-
teins, ligands, growth factors, receptors,13,34 and micro RNA (miRs).38
Our study demonstrated the novel findings that microparticles also carry
ET-1, but more importantly, we have shown that VEGFi treatment indu-
ces a phenotypic change of microparticles so that they induce
endothelial cell signalling through ET-1-dependent pathways. In support
of these findings, previous studies demonstrated that tyrosine kinase
inhibitor-induced hypertension is associated with increased circulating
levels ET-1 levels.26–29 However, the source of ET-1 in those studies was
unclear.
Mechanisms underlying the interaction between microparticles and
effector target cells are complex and might be related to diffusion
through the plasma membrane or via receptor or integrin interac-
tion,39,40 followed by internalization of the microparticles into target cell.
Additionally, microparticles can release their cargo into the extracellular
space13,41,42 and mediate effects through a paracrine-like manner. For
example, neutrophil-derived microvesicles carry cytokines, which func-
tion as pro-inflammatory mediators.43 Cancer cell-derived micropar-
ticles release metalloproteases and promote tumour invasion and
metastases44,45 and PMPs transfer miR-142 into endothelial cells causing
A
B C
Figure 3 Post-treatment MPs increase pre-pro-ET-1 gene expression in HAEC. (A) Graph represents the expression of ET-1 assessed by immunoblot-
ting in plasma isolated MPs from patients pre-treatment and post-treatment with VEGFi (n=17). The image shows six samples from one patient and is
representative of the 17 patients, pre-treatment and post-treatment. (B) Pre-pro-ET-1 mRNA levels assessed by qPCR in HAEC exposed to total pre-
treatment (grey bar) and post-treatment (black bar) MPs for 8 h and non-stimulated (NS, white bar) HAEC (n=6–7). (C) ET-1 levels measured by ELISA
in media fromHAEC stimulated with vehicle or vatalanib (VEGFi) for 8 h (n=6–7). Results represent the mean ± SEM. Data were analysed using t-test or
one-way ANOVA followed by a post hoc Tukey test when appropriate. *P<0.01 vs. NS, †P<0.05 vs. pre-treatment. S, subject.
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..endothelial dysfunction.38 Regarding our findings, ET-1 containing micro-
particles may influence endothelial cell function by delivering ET-1 to ef-
fector cells, where it mediates actions through endothelial cell ETAR and
ETBR as well as by stimulating de novo endothelial production of ET-1.
Endothelial dysfunction is associated with oxidative stress46,47 and our
group has already demonstrated that microparticles themselves stimu-
late endothelial ROS formation and inflammatory responses, processes
that are up-regulated in hypertension.16,48 In the current study, only
microparticles from VEGFi-treated patients caused an increase in endo-
thelial ROS production that promotes endothelial dysfunction and in-
flammation. These findings suggest that VEGFi treatment causes
endothelial dysfunction and shedding of microparticles and that the phe-
notype of these cell-derived elements exhibit a pro-inflammatory pheno-
type. Other studies also demonstrated that microparticles from cells
exposed to stressed conditions such as hyperglycaemia and angioten-
sin II stimulation, induce an increase in O2_production in endothelial
cells16 and monocytes.49 These phenomena have also been linked to
eNOS uncoupling,26 which further increases ROS generation.
Moreover, microparticles from VEGFi-treated patients reduced
endothelial eNOS activation and NO levels, processes linked to
ETBR. ET-1/ETBR signalling typically causes endothelial vasodilation
via NO and prostacyclin production.50 However, in the context of
VEGFi, where microparticles promote an oxidative milieu, the pro-
tective effects of ETBR may shift to an injurious scenario with in-
creased production of ONOO-, which is highly unstable and
damaging. In support of this notion, in patients with obstructive sleep
apnoea syndrome microparticles induce angiogenesis through a
mechanism involving endothelial-derived ET-1/ETBR.51
Our study clearly demonstrates that VEGFi induces a change in micro-
particles to a pro-inflammatory phenotype as evidenced by the significant
increase in expression of endothelial pro-inflammatory mediators includ-
ing IL-6, TNF-a, MCP-1, Cox2, VCAM-1, and iNOS. Other studies have
also shown that microparticles from various cell types including mono-
cytes, platelets and endothelial cells, promote inflammation and apopto-
sis.52–58 Some of these processes are mediated by ROS and, as we show,
the ET-1 system may also be important. Accordingly, it is possible that
drugs targeting the ET-1 system may protect against the injurious vascu-
lar effects of VEGFi.
A
B
Figure 4 MPs increase ROS production in HAEC, which is attenuated by ET-1 receptors antagonism. NADPH-stimulated O-2 production was assessed
by lucigenin assay in (A) HAEC exposed to total pre-treatment and post-treatment MPs for 5, 15, 30, and 60min (n=5–6) and (B) HAEC exposed to
post-treatment MPs for 5, 30, and 60min in presence or absence of BQ123 (ETA antagonist, 1mmol/L) or BQ788 (ETB antagonist, 1mmol/L) (n=5–9).
Results represent the mean ± SEM. Data were analysed using one-way ANOVA followed by a post hoc Tukey test. *P<0.05, **P<0.01, ***P<0.001 vs.
NS; /P<0.05 vs. post-treatment.
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..While we have clearly demonstrated that VEGFi treatment influences
the formation and phenotype of microparticles in cancer patients, our
study does not provide any insights regarding underlying cardiovascular
risk factors, including hypertension, which may impact microparticle sta-
tus. We are also unable to comment on the effect of VEGFi treatment
on the ‘proteome’ of microparticles, but such informationwould provide
insights on molecular mechanisms and signalling associated with the phe-
notypic changes after treatment. In addition, our study was not designed
to assess relationships between microparticles and blood pressure in
VEGFi-treated patients, but this is certainly an interesting notion that
warrants further study.
In summary, we show that VEGFi treatment in cancer patients pro-
motes formation of pro-inflammatory MPs that also act as vehicles to
transport ET-1 to effector target cells, where it promotes ET-1 produc-
tion, ROS production and inflammation. These processes, which are me-
diated through ET receptors, suggest a feedforward system where MP-
containing ET-1 stimulate the endothelial ET-1 system, which in turn
influences ROS and NO generation (Figure 7). Our novel findings define
a novel molecular mechanism involving interplay between micropar-
ticles, the ET-1 system and endothelial cell pro-inflammatory and redox
signalling, which may be important in cardiovascular toxicity and hyper-
tension in cancer patients treated with VEGFi.
5. Perspectives and significance
VEGFi are very effective anti-cancer drugs, however, they cause unwanted
cardiac and vascular toxicities through ill-defined mechanisms. Our new
findings demonstrate that microparticles are potential biomarkers of
VEGFi-induced endothelial injury and may be important mediators of ET-
1-mediated redox- and pro-inflammatory endothelial cell signalling. These
findings identify a putative mechanism whereby VEGFi-induced endothe-
lial damage begets further endothelial damage, processes that may con-
tribute to cardiovascular complications in VEGFi-treated cancer patients.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
A B
C D
Figure 5 MPs reduce eNOS/NO signalling and increases ONOO- in HAEC via ETB receptor. (A) Phosphorylation of eNOS (Thr
495) was determined
by immunoblotting in non-stimulated HAEC or cells exposed to total MPs (106 MPs/mL) isolated from patients’ plasma pre-treatment and post-treat-
ment with VEGFi for 5 and 15min (n=4). (B) eNOS phosphorylation was assessed in HAEC stimulated with total post-treatment MPs (15min). Cells
were also pre-treated with BQ788 (ETB antagonist, 1mmol/L), added 30min before the stimulation with MPs. Values were normalized by total eNOS ex-
pression (n=5). (C) Nitric oxide (NO) production was determined by DAF2-DA fluorescence in HAEC exposed to total post-treatment MPs in pres-
ence and absence of BQ788 (n=6). (D) Peroxynitrite (ONOO-) levels were determined by nitrotyrosine ELISA in HAEC exposed to total post-
treatment MPs in presence and absence of BQ788 (n=5–6). Values from DAF2-DA and nitrotyrosine ELISA were normalized by protein amount.
Results represent the mean ± SEM. Data were analysed using one-way ANOVA followed by a post hoc Tukey test. *P<0.05 vs. NS; †P<0.05 vs. pre-treat-
ment;u vs. MPs.
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